- Home
- RAC vs PBYI Comparison
RAC vs PBYI Comparison
Compare RAC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAC
- PBYI
- Stock Information
- Founded
- RAC 2024
- PBYI 2010
- Country
- RAC United States
- PBYI United States
- Employees
- RAC N/A
- PBYI N/A
- Industry
- RAC
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- RAC
- PBYI Health Care
- Exchange
- RAC Nasdaq
- PBYI Nasdaq
- Market Cap
- RAC 301.5M
- PBYI 263.4M
- IPO Year
- RAC 2025
- PBYI N/A
- Fundamental
- Price
- RAC $10.39
- PBYI $4.95
- Analyst Decision
- RAC
- PBYI Strong Buy
- Analyst Count
- RAC 0
- PBYI 1
- Target Price
- RAC N/A
- PBYI $7.00
- AVG Volume (30 Days)
- RAC 18.4K
- PBYI 418.9K
- Earning Date
- RAC 01-01-0001
- PBYI 11-06-2025
- Dividend Yield
- RAC N/A
- PBYI N/A
- EPS Growth
- RAC N/A
- PBYI 434.29
- EPS
- RAC N/A
- PBYI 0.97
- Revenue
- RAC N/A
- PBYI $238,062,000.00
- Revenue This Year
- RAC N/A
- PBYI N/A
- Revenue Next Year
- RAC N/A
- PBYI N/A
- P/E Ratio
- RAC N/A
- PBYI $5.08
- Revenue Growth
- RAC N/A
- PBYI 8.63
- 52 Week Low
- RAC $9.87
- PBYI $2.32
- 52 Week High
- RAC $10.42
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- RAC N/A
- PBYI 45.94
- Support Level
- RAC N/A
- PBYI $5.14
- Resistance Level
- RAC N/A
- PBYI $5.52
- Average True Range (ATR)
- RAC 0.00
- PBYI 0.25
- MACD
- RAC 0.00
- PBYI -0.06
- Stochastic Oscillator
- RAC 0.00
- PBYI 17.82
About RAC Rithm Acquisition Corp. Class A Ordinary Shares
Rithm Acquisition Corp is a blank check company.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.